We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $88.82, moving +0.6% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.86% for the day. At the same time, the Dow lost 0.9%, and the tech-heavy Nasdaq lost 2.76%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 4.19% over the past month. This has outpaced the Medical sector's loss of 3.61% and the S&P 500's gain of 1.01% in that time.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on November 6, 2024. In that report, analysts expect Gilead Sciences to post earnings of $1.62 per share. This would mark a year-over-year decline of 29.26%. In the meantime, our current consensus estimate forecasts the revenue to be $6.99 billion, indicating a 0.86% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.76 per share and a revenue of $27.67 billion, indicating changes of -44.05% and +2.04%, respectively, from the former year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.51% lower within the past month. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 23.46. This expresses no noticeable deviation compared to the average Forward P/E of 23.46 of its industry.
It is also worth noting that GILD currently has a PEG ratio of 3.07. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry had an average PEG ratio of 2.44 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 79, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $88.82, moving +0.6% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.86% for the day. At the same time, the Dow lost 0.9%, and the tech-heavy Nasdaq lost 2.76%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 4.19% over the past month. This has outpaced the Medical sector's loss of 3.61% and the S&P 500's gain of 1.01% in that time.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on November 6, 2024. In that report, analysts expect Gilead Sciences to post earnings of $1.62 per share. This would mark a year-over-year decline of 29.26%. In the meantime, our current consensus estimate forecasts the revenue to be $6.99 billion, indicating a 0.86% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.76 per share and a revenue of $27.67 billion, indicating changes of -44.05% and +2.04%, respectively, from the former year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.51% lower within the past month. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 23.46. This expresses no noticeable deviation compared to the average Forward P/E of 23.46 of its industry.
It is also worth noting that GILD currently has a PEG ratio of 3.07. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry had an average PEG ratio of 2.44 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 79, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.